Orange High School senior Aanya Chepyala was recently named the Kiwanis Club of Lander Circle Senior of the Month for ...

Bristol Myers Squibb hasn’t had much luck with its efforts to develop cancer treatments called T cell engagers. But the pharmaceutical company isn’t done pursuing this type of targeted cancer therapy, ...

Some members of the maker community are distraught about Arduino’s new terms of service (ToS), saying that the added rules put the company’s open source DNA at ...

The future of electric vehicles depends on battery packs that are safe, efficient, and easy to maintain. Wireless battery-management systems introduce a new way to cover all of these needs. What’s the ...

Forbes contributors publish independent expert analyses and insights. Chief Analyst & CEO, NAND Research. Qualcomm, a company built on selling chips to companies like Samsung and Apple in volumes of ...

Bristol Myers Squibb is securing an opportunity to compete in the next generation of cell therapies through the $1.5 billion acquisition of Orbital Therapeutics, a startup with a lead program nearing ...

In a deal that surprised some industry observers, chipmaker Qualcomm has agreed to buy Arduino, which is best known for supplying microcontrollers to the DIY community. The acquisition, whose terms ...

Qualcomm's acquisition gives it access to millions of developers in the Arduino ecosystem while also supporting its platform strategy for embedded devices, which now extends across hardware, software, ...

Qualcomm announced Tuesday it will acquire Arduino for undisclosed terms. The chipmaker said the Italy-based company would become an independent subsidiary of Qualcomm. In this article Qualcomm wants ...

BMS-986504, a first-in-class methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) targeting agent, showed promising antitumor activity in heavily pretreated patients with ...

Bristol Myers Squibb (BMS) has announced it will buy the oncology drug developer Mirati Therapeutics, setting it up to gain Krazati (adagrasib), a KRAS inhibitor that received approval from the US ...

Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the next five years toward U.S. research and development (R&D), ...